Search Results 501-510 of 17563 for Toxin

1. A Study to Evaluate the Safety and Tolerability of Rebiotix RBX2660 (microbiota suspension) in Subjects with Recurrent Clostridium difficile Infection - Mayo Clinic

   difficile toxin within 30 days prior to or on date of enrollment. Is currently taking or was just prescribed antibiotics to control CDI related diarrhea at ...

2. A Study to Evaluate the Effectiveness and Safety of P276-00 for Mantle Cell Lymphoma that has Returned and/or is Resistant to Treatment - Mayo Clinic

   Prior treatment with monoclonal antibodies or any radio- or toxin- immunoconjugates within 3 months of study drug administration. However rituximab treatment ...

3. Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia - Mayo Clinic

   ... toxin exposure); Children with histories of resolved bronchiolitis, resolved viral pneumonias and well-controlled asthma are eligible, even if they are ...

4. A Trial of the Effectiveness, Safety, and Tolerability of a Single Oral Administration of CP101 for the Prevention of Recurrent Clostridioides difficile Infection (PRISM4) - Mayo Clinic

   Documented positive stool test by local laboratory for toxigenic C. difficile (toxin EIA or polymerase chain reaction [PCR]-based testing) for the current ...

5. Publications - Vivek N. Iyer, M.D., M.P.H. - Mayo Clinic

   Bilateral Thyroarytenoid Botulinum Toxin Type A Injection for the Treatment of Refractory Chronic Cough. JAMA Otolaryngol Head Neck Surg. 2016 Sep 1; 142 (9): ...

6. A Study to Evaluate the Effectiveness and Safety of Ralinepag To Improve Treatment Outcomes in Peripheral Arterial Hypertension (PAH) Patients - Mayo Clinic

   Drugs or toxins induced PAH based on prior exposure to drugs, chemicals, or toxins, such as fenfluramine derivatives, other anorexigens, toxic rapeseed oil; or ...

7. A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity - Mayo Clinic

   - Participants who are either naïve to Botulinum toxin type A (BoNT-A) for ULS or who have been previously treated with BoNT-A for ULS; - Participants with ...

8. A Study of Environmental Risk Factors for the Anti-Synthetase Syndrome - Mayo Clinic

   Myositis that has clearly developed as the result of a drug, toxin or other exposure and has resolved after discontinuation of the exposure to that agent.

9. Research of Experimental COVID-19 Therapeutics Explained - Mayo Clinic News Network

   According to an article in Nature, antibodies were first discovered in the blood of animals exposed to diphtheria or tetanus toxin more than 100 years ago.

10. Hand Surgery Clinical Trials - Mayo Clinic Research

    ... toxins. Cosmetological care for facial skin aging includes daily skin care, correct sun protection and aesthetic non-invasive procedures. 80 participants ...